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Abstract 
Purpose: To develop docetaxel (DTX)- and alendronate (ALN)-loaded, chitosan (CS)-conjugated poly-
lactide-co-glycolide (PLGA) nanoparticles (NPs) to increase therapeutic efficacy in osteosarcoma cells.  
Methods: Drug-loaded PLGA NPs were prepared by nanoprecipitation and chemically conjugated by 
the carboxylic group of PLGA to the amine-bearing CS polymer. The nanocarrier was characterized by 
dynamic light scattering, transmission electron microscopy, scanning electron microscopy, and 
differential scanning calorimetry as well as by in vitro drug release and cell culture studies. 
Results: NP size was within the tumour targeting range (~200 nm) with an effective positive charge (20 
mV), thus increasing cellular uptake efficiency. Morphological analysis revealed clear spherical particles 
with uniform dispersion. The NPs exhibited identical sustained release kinetics for both DTX and ALN. 
CS-conjugated PLGA with dual-drug-loaded (DTX and AL) NPs showed typical time-dependent cellular 
uptake and also displayed superior cytotoxicity in MG-63 cells compared with blank NPs, which were 
safe and biocompatible.   
Conclusion: Combined loading of DTX and ALN in NPs increased the therapeutic efficacy of the 
formulation for osteosarcoma treatment, thus indicating the potential benefit of a combinatorial drug 
regimen using nanocarriers for effective treatment of osteosarcoma. 
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Osteosarcoma is the most prevalent malignant 
bone cancer. It commonly occurs in children and 
adolescents: approximately 400 cases per year 
are diagnosed in the United States alone [1]. 
Osteosarcoma mostly arises in the metaphyseal 
ends of long bones, and is characterized by 
malignant metastatic tumours that differentiate as 
cartilage and bone [2]. The survival rate is nearly 
20 % with surgery; however, it increases to 70 % 
when combined with anticancer drug therapy. 
Thus, surgery and chemotherapy play a vital role 
in the treatment of osteosarcoma. A recently 
multi-drug regimen reportedly improved 
osteosarcoma treatment [3]. 
 
Combination therapy has been considered a 
promising strategy for improving therapeutic 
efficiency and minimising side effects [4]. The 
combination of two or more chemotherapeutic 
drugs may act synergistically in cancer cell 
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suppression [5,6]. In this study, docetaxel (DTX) 
and alendronate (ALN) were selected as a 
unique drug combination for the synergistic 
treatment of bone cancers. 
 
DTX is a frontline chemotherapeutic agent that is 
active against a wide spectrum of cancers. DTX 
acts on the microtubules of the malignant cell to 
suppress its proliferation, killing cancer cells by 
inducing a G2/M phase arrest of the cell cycle. 
Despite excellent therapeutic potential, DTX 
treatment results in severe adverse effects, 
including neutropenia, anaemia, and 
hypersensitivity reactions [7]. ALN is used 
because of its strong osteoprotective properties 
and its affinity for bone cancer cells. It belongs to 
the class of amino bisphosphonates (NBP), and 
is in the fourth class of the Biopharmaceutics 
Classification System (BCS) because of its poor 
solubility and low bioavailability [8,9].  
 
Nanotechnology-based formulation is a 
promising alternative in cancer treatment. Poly-
lactide-co-glycolide (PLGA) exhibits excellent 
biocompatibility and biodegradability, and has 
been extensively used as a carrier for drug 
delivery [10]. This system extravasates solid 
tumours into the tumour site by passive targeting 
via an enhanced permeability and retention effect 
(EPR). However, the PLGA nanocarrier itself is 
not sufficient. Surface modification of PLGA with 
certain hydrophilic polymers enables these 
nanoparticles (NPs) to increase their selectivity 
for cellular binding and internalization [11]. For 
example, chitosan (CS), a biocompatible and 
nontoxic cationic polysaccharide, is commonly 
used for surface modifications. 
 
The aim of this study was to develop a CS-
coated PLGA nanocarrier system for the 
combined delivery of DTX and ALN to 






PLGA-COOH with a lactide to glycolide ratio of 
50:50 and an average molecular weight of 15 
kDa was purchased from Ji’nan Daigang 
Biological Co. Ltd (Shandong, China). CS 
(deacetylation degree, >84 %) was purchased 
from Zhanjiang Xinmao Chemical & Glass 
Company (Zhanjiang, China). DTX, ALN, and 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma 
Chemical Co., USA). All chemicals were 
analytical grade and used without further 
purification. 
 
Preparation of CS-coated PLGA NPs 
containing DTX and ALN 
 
DTX-loaded PLGA NPs were prepared by 
solvent diffusion (nanoprecipitation) as previously 
reported [12]. The organic phase (acetone) 
containing DTX (15 mg) and ALN (15 mg) and 
PLGA (200 mg) in a 1:1:1 ratio (v:v) was slowly 
injected (0.5 mL/min) into 20 mL of aqueous 
phase containing Poloxamer 188 (0.5 % w/v) as 
a stabilizer. The resulting NPs were recovered by 
centrifugation at 25,000 rpm for 30 min and 
purified by dialysis against water and lyophilized 
for 48 h. 
 
The freeze-dried PLGA nanoparticles were 
dispersed in phosphate buffered saline (PBS) 
solution (pH 6.0) under bath sonication at 37 °C. 
N-hydroxysuccinimide (NHS) and N-(3-
dimethylaminopropyl)-N′ ethyl carbodiimide 
hydrochloride (EDC·HCl) was added to activate 
the carboxyl group of PLGA. Different 
concentrations of CS were added into the above 
solution and the reaction was allowed to continue 
for 24 h. The excess EDC, NHS, and unreacted 
CS were eliminated by centrifugation. A 
schematic illustration of the preparation of dual-
drug-loaded CS-coated PLGA NPs is shown in 
Figure 1. 
 
Particle size and zeta potential measurement 
 
The hydrodynamic diameter of the NPs was 
measured using a dynamic light scattering (DLS) 
technique. A Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, UK) was used to 
measure the size at room temperature with an 
angle of detection of 176°. Zeta potential 
measurements were performed with a detection 
angle of 17° and calculated using the 
Smoluchowski model. The samples were suitably 
diluted (200 mg/mL) with double-distilled water 
such that the mean count rate was approximately 




Morphological studies of the NPs were 
conducted using transmission electron 
microscopy (TEM) and field emission scanning 
electron microscopy (FE-SEM). TEM (H-7600; 
Hitachi, Japan) was performed by staining a 
small drop of the NP suspension with a 2 % 
phosphotungstic acid (PTA) solution. The stained 
sample was deposited onto a carbon coated 
copper grid and dried for 30 min at room 
temperature.  
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Figure 1: Schematic illustration of the preparation of docetaxel (DTX)- and alendronate (ALN)-loaded chitosan 
(CS)-conjugated polylactide-co-glycolide (PLGA) nanoparticles 
 
The samples were examined under an 
acceleration voltage of 100 kV in conventional 
TEM-mode. FE-SEM was performed with the 
help of an electron microscope (JSM-7610F 
scanning electron microscope, Tokyo, Japan). 
Lyophilized NP samples were reconstituted with 
deionized water and spread onto a carbon tape 
over a stub. The samples were vacuum-dried 
and gold coating was applied using an ion 
sputtering device. The gold-coated samples were 
vacuum-dried and examined under an electron 
microscope. 
 
Differential scanning calorimetry (DSC)  
 
DSC measurement of ALN, DTX, and PLGA-
ALN-DTX CS was performed using a calorimeter 
(Mettler TA4000, Mettler Toledo, OH, USA). 
Empty aluminum pans were used as a reference 
and samples were carefully placed in another 
aluminum pan. The measurement was done in 
an inert atmosphere within a temperature range 
of 30 – 200 °C at 10 °C/min.  
 
Determination of loading efficiency 
 
Loading efficiency was calculated from the total 
amount of drug added versus the amount of drug 
entrapped in the NPs. Briefly, the drug-loaded 
complex was pushed through an Amicon 
centrifugal filter by centrifuging at 5,000 rpm for 
10 min. The filtrate was analysed for 
unentrapped drug using high-performance liquid 
chromatography (HPLC) at 320 nm and 230 nm. 
Standard curves were individually plotted for ALN 
and DTX. Loading efficiency (L) was calculated 
as in Equation 1. 
 
L (%) = {(Dt Df)/W}100 ……………………. (1) 
 
where Dt, Df, and W are the total amount of DTX, 
the amount of free DTX, and the total weight of 
NPs, respectively. 
 
In vitro release studies 
 
In order to investigate the release of DTX and 
ALN from CS-PLGA NPs, a fixed amount  (1 
mg/mL) of the drug-loaded NPs was incubated in 
10 mL of phosphate buffer solution PBS pH 7.4, 
ionic strength 0.1 M) in a dialysis bag (molecular 
cut-off of 10 kDa), at 37 °C with gentle magnetic 
stirring (100 rpm). At fixed time intervals, 1 mL of 
the supernatant was withdrawn and replaced 
with fresh buffer. The amount of DTX and ALN 
released in the collected samples was 
determined by HPLC as described above. All 




MG-63 cells were obtained from American Type 
Culture Collection (ATCC; Rockville, MD, USA). 
The cells were grown in Dulbecco’s Modified 
Eagle Media (DMEM) DMEM  supplemented with 
10 % fetal bovine serum (FBS), 100 units/mL 
penicillin, and 100 mg/mL of streptomycin. Cells 
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Cell viability was used to determine the cytotoxic 
potential of individual formulations as determined 
by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay. 
Briefly, cells were seeded into a 96-well plate at 
a seeding density of 0.5 × 104 cells in 0.1 mL 
growth medium and incubated for 48 h. The 
following day, the cells were treated with the 
respective formulations (DTX, ALN, DTX-ALN, 
and DTX-ALN-CS-PLGA NPs) at increasing 
concentrations from 0.01 mg/mL to 10 mg/mL. 
The respective formulations were incubated for 
24 h. At each time interval, cells were washed 
with PBS and treated with MTT solution (5 
mg/mL in serum-free media) and incubated for 
another 4 h. The resulting formazan crystals 
were dissolved in 0.1 mL of dimethyl sulfoxide 
(DMSO). The mixture was gently shaken in a 
microplate reader before measuring the 
absorbance at 570 nm. Cell viability was 
calculated after subtracting each value from the 
control. Each test was carried out 8 times (n = 8). 
 
Flow cytometry studies 
 
MG-63 cells (5 × 105) were seeded in a 6-well 
plate and incubated for 24 h at 37 °C. The cells 
were treated with PLGA and CS-PLGA NPs for 1 
h. The cells were washed 3 times with PBS, 
trypsinized, centrifuged, resuspended in PBS, 
and analysed on a fluorescence-activated cell 





Student’s t-tests were used to determine the 
differences among groups. The results are 
presented as mean ± standard deviation (SD; n = 
3) with p < 0.05 considered statistically 
significant. Statistical significance was 
determined using SPSS software (version 16; 




Characteristics of DTX- and ALN-loaded CS-
conjugated PLGA NPs 
 
In the present study, a unique combination of 
DTX and ALN was used to treat osteosarcoma 
cells. For this purpose, CS was conjugated to the 
carboxylic group of PLGA and loaded with DTX 
and ALN. The dual-drug-loaded NPs were 
successfully prepared with high drug entrapment 
of 83.7 ± 1.23 and 71.89 % corresponding to 
6.51 and 5.21 % drug loading of DTX and ALN. 
The particle size of the PLGA NPs (PNP) and 
CS-coated PLGA NPs (CPNP) was observed to 
be 165 ± 1.72 and 202 ± 4.2 nm respectively 
(Figure 2a). The zeta potential of the NPs was 
evaluated to confirm the polymer substitution and 
stability. The zeta potential of the PNP was 
negatively charged at −23.67 ± 3.21 because of 
the carboxylic groups. The zeta potential 
changed to 21.37 ± 1.28 after coating with 





The morphology of both NPs was evaluated 




DSC was performed to assess the physical state 
of the drug after encapsulation in the NP as the 
physical state could influence the in vitro and in 
vivo properties of the drug. Figure 3 shows the 
DSC thermograms of pure DTX, ALN, PNP, and 
CPNP. 
 
The melting endothermic peak of pure DTX 
appeared at 173 °C, while that of ALN appeared 
at 128 °C, indicating its sharp crystalline nature. 
The melting peak of both drugs was not detected 
in the NP formulation, indicating that the drugs 
were successfully incorporated into the NPs and 
present in the molecular dispersed and 
amorphous forms. It is worth noting that the 
crystalline form of the drug is not active and is 
not effective or stable in the systemic circulation. 
The amorphous form of the drug, however, 
circulates freely [13].  
 
In vitro drug release 
 
The release of DTX and ALN from CPNP was 
performed in PBS (pH 7.4) to simulate the 
physiological conditions of the human body. An 
initial release of approximately ~30 % from the 
NPs was observed in the first 8 h, suggesting 
that a significant portion of the drug was present 
on the surface of the NP, which was released 
upon contact with the medium (Figure 4). 
Following this initial release, a more sustained 
release of the drug was observed for up to 48 h, 
demonstrating the capacity of the carrier to 
withhold the drug while in systemic circulation. 
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Figure 2: (a) Particle size distribution of chitosan (CS)-coated polylactide-co-glycolide nanoparticles CPNP; (b,c) 
transmission electron microscope (TEM)TEM images of polylactide-co-glycolide (PLGA NPs) and CS-conjugated 
PLGA NPs; (d,e) scanning electron microscope (SEM) images of PLGA NPs and CS-conjugated PLGA NPs. 
Panels b and c present TEM images of PNP and CPNP in the dried state, where PNPs are spherical in shape 
and uniformly distributed on the TEM grid. The particle shape was further confirmed by field emission scanning 




Figure 3: Differential scanning colorimetry (DSC) thermograms of free ALN, DTX, PLGA, and CPNP 
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Figure 4: Drug release of ALN and DTX from chitosan (CS)-coated polylactide-co-glycolide nanoparticles 
(CPNP) in release buffer CPNPs in PBS 
 
 
Figure 5: Flow cytometry analysis of cellular uptake (a, b) of PNPs and CPNPs in osteosarcoma cancer cells; (c) 
cytotoxicity assay of blank nanoparticles; (d) cytotoxicity assay of free drugs and drug-loaded nanoparticles 
 
Cellular uptake  
 
Flow cytometry analysis was performed to 
confirm the cellular uptake of CPNPs in MG-63 
cancer cells. To accomplish this, the drug was 
replaced with the fluorescent probe Rhodamine 
B. A remarkable increase in fluorescence 
intensity was observed after 30-min incubation 
(Figure 5a, b). Cellular uptake increased further 
when the incubation time was extended to 1 h. 
 
In vitro cytotoxicity 
 
The in vitro cytotoxicity of blank PLGA NPs and 
blank CS-coated PLGA NPs was investigated in 
MG-63 cancer cells. Cancer cells were exposed 
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to the polymers (0.1 – 1,000 µg/mL). Blank NP 
treatment resulted in high cell viability, 
suggesting that the polymers have excellent 
biocompatibility (Figure 5c, d). The lack of carrier 
cytotoxicity is advantageous for cancer cell 
targeting. MG-63 cells were also treated with free 
DTX, ALN, and DTX/ALN-loaded combined NPs. 
Both DTX and ALN treatment resulted in typical 
concentration-dependent cytotoxicity after 24 h 
incubation. Moreover, DTX was more effective 




First, DTX- and ALN-loaded PLGA NPs were 
prepared, and the carboxylic groups of PLGA 
NPs were conjugated to CS by an EDC/NHS 
reaction. PLGA NPs have a reduced affinity for 
cancer cells due to the negatively charged 
carboxyl groups on the PLGA surface. CS was 
therefore introduced to modify the surface 
charge, and improve chemotherapeutic efficacy. 
The positively charged NP system thus 
increased cellular uptake efficiency. The increase 
in the size of NP was attributed to the presence 
of the high molecular weight CS on the NP 
surface. It also indicated a definite deposition of 
mass on the NPs. The zeta potential changed to 
a positive charge after coating with a cationic 
polymer with an active amine functional group. 
The presence of this positive charge was 
expected to enhance the interaction between the 
cancer cells and NPs and facilitate cellular 
uptake [12].  
 
The spherical nature of the NP was attributed to 
the self-assembly of the polymer in the presence 
of surfactant. CPNPs are also spherical particles 
with monodispersion, although the overall 
particle size is larger. The greyish shell on the 
NP surface might have been the CS coating, 
which increased the particle size. PNPs initially 
consisted of a smooth surface, while the CS 
coating slightly roughened the surface. 
Nevertheless, a spherical-shaped particle in the 
nanodimension is ideal for cancer tissue 
targeting. 
 
Importantly, no significant difference in the 
release pattern of DTX and ALN was observed, 
indicating that the substitution of CS on the NP 
surface did not influence drug release from the 
delivery system [13]. The release data were fit to 
mathematical models, and the release kinetics 
were confirmed by fitting to the Higuchi model (r 
= 0.999), with the release profile indicating a 
diffusion-based release. A controlled release 
system in which the drug is released to the 
tumour tissue at a steady rate is of significant 
importance. 
High cellular uptake efficiency is also necessary 
for the successful delivery of the drug to the 
tumour. Our results suggest that positively 
charged nanocarriers could be efficiently 
internalized in cancer cells. DTX/ALN-loaded 
CPNPs exhibited a superior cancer killing effect 
compared with either drug alone. Interestingly, 
introduction of DTX/ALN-loaded CPNPs resulted 
in only 45 % cell viability, indicating its 
cytotoxicity. The IC50 value, or the concentration 
required to kill 50 % of cancer cells, was 
investigated: the IC50 value of DTX/ALN-loaded 
CPNPs was nearly 20 times lower than that of 




A unique DTX- and ALN-conjugated CS-coated 
PLGA nanoparticle formulation was prepared 
and evaluated for its potential in targeting 
osteosarcoma cells. The two-drug-loaded NP 
showed a superior cancer killing effect in MG-63 
cancer cells and was safe and biocompatible. 
Combined loading of DTX and ALN increased 
the therapeutic efficacy in osteosarcoma 
treatment. Thus, combinatorial drug regimens 
using nanocarriers hold promise for the effective 
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